Singapore dengue cases rise as dominant strain shifts despite overall decline

Singapore's dengue picture has grown complicated. The numbers look good on paper—1,180 cases in the first half of 2026, down more than half from the 2,583 recorded in the same stretch of 2025. But beneath that headline sits a troubling shift that epidemiologists are watching closely: the virus that dominates the island has changed, and history suggests that change could mean trouble ahead.

For months, the story in Singapore has been one of success. Project Wolbachia, an initiative to suppress the Aedes mosquito population, has helped drive dengue infections down year after year. But the seasonal rhythm of the disease is reasserting itself. Between April and June, cases nearly doubled compared to the first quarter—770 infections versus 410—as the island entered its peak dengue season, which runs from May through October.

The real concern lies in which strain is now circulating. In January, DENV-3 accounted for just under one-fifth of cases. By June, it had become the dominant serotype, responsible for nearly 60 percent of infections. This matters because people who have been infected by one dengue strain retain little protection against the others. When a new serotype takes hold, the population's collective immunity drops, and cases tend to spike. The pattern is not unique to Singapore. Across the region, the same shift is driving outbreaks. Malaysia reported 42,848 dengue cases as of mid-July—a 35 percent jump from the same point in 2025—with DENV-3 now dominant there as well. The toll has been severe: 34 deaths recorded so far this year, compared to 19 in the same period of 2025. Vietnam has seen even larger numbers, with more than 50,000 cases in the first five months of 2026, double the previous year's total.

Paul Tambyah, a professor of medicine at the National University of Singapore and immediate past president of the Asia Pacific Society of Clinical Microbiology and Infection, sees the serotype switch as the most likely driver of these regional spikes. He points out that the same pattern has repeated itself with other viral infections—influenza, COVID-19—whenever new strains emerge. The movement of people across borders, particularly between Malaysia and Singapore, could accelerate the spread. "Singapore has already seen a rise in the number of dengue cases in the last quarter and this is likely to continue," Tambyah said. Yet he acknowledged an uncertainty: sudden reversals have happened before, with DENV-2 potentially reasserting dominance, though scientists do not fully understand why such switches occur.

Other experts offer a more measured view. Ooi Eng Eong, a professor in the emerging infectious diseases programme at Duke-NUS Medical School, notes that Singapore's vector control program has created a buffer—reduced transmission and longer intervals between major outbreaks. An outbreak in Malaysia, he suggests, does not automatically translate into one in Singapore. He also points to a complicating factor: genetic variations within each serotype can affect how readily the virus spreads. Some recent dengue outbreaks have been driven by these genetic changes rather than by low population immunity to a new strain. "Our ability to predict epidemics based on the genomic sequence of the viruses is still very much in its infancy," Ooi said.

What remains clear is that Singapore's defenses are not passive. Tambyah emphasized that rapid case detection, surveillance, and timely vector control—the methods that have worked before—remain the best tools for moderating a rise in cases. Whether the island can hold the line as the region burns remains an open question, but the machinery for doing so is in place and tested.